Posts by Muhammad Shuaib Abid
#TCT2025
TCT 2025 | October 28 | 11:00 AM Presentation PCI of Native Coronary Artery versus SVG in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR):
A Multicenter, Open-label, Randomized Trial
@crfheart
@TCT_ME_
@TCTConference
@aayshacader
10.iMODERN:
(iFR- vs. Cardiac MRI-Guided Revascularization of Non-Culprit Lesions in STEMI)
11.PROMISE
Personalized vs. Conventional Management of Patients with MINOCA
12.TUXEDO-2:
Supraflex Cruz vs. Xience DES in Patients with Diabetes and Multivessel CAD
6.SUMMIT
(1 year outcome of Tendyne TMVR for severe MAC)
7.ENCIRCLE
(1 year outcome of Sapiens TMVR for pts unsuitable for surgery)
8.PROCTOR.
Native vessel vs SVG PCI in pts with CABG
9.STRIVE:
Low-Dose r-tPA vs. Placebo in STEMI With Large thrombus burdon
Late Breaking RCT TCT 2025.
...........
1.SELUTION DeNovo:
Sirolimus DCB vs DES in de Novo lesions
2.SELUTION4ISR
Sirolimus DCB vs DES in ISR
3.Short-CUT
IVL vs CB in calcified lesions
4.VICTORY
IVL vs Super High pressure balloon in calcified lesions
5.PARTNER 3:
(7years outcome)
#TAVI
#NYValves2025
#APValves2025
Wires used for TAVI Crossing
3 commonly used wires are
1.Ampltaz
2.Confida
3.Safari
...
Name of all wires
▪︎Hightorque Supracore
▪︎ConfidaTMBrecker
.
▪︎Amplatz Family
▪︎Back up Meier TM wire
.
▪︎Lunderqvista extra stiff wire
.
▪︎Safari wires
#Mitra Clip was approved by FDA forÂ
1.Primary MR based on #EVEREST II Trial in 2013
2.Secondary MR based on #COAPT Trial in 2019
@crfheart.bsky.social
@scainews.bsky.social
Alfieri stitch.(Bow-tie” or “Figure 8” procedure)
....
Dr Ottavio Alfieri ,an italian cardiothoracic surgeon first performed Surgical edge to edge repair of Mitral valve in 1991 for Symptomatic severe MR.He brought this idea after encountering a Pt with congenital double orifice.
#Cardiobird
STEMI & MVD
When 2 branches r arising around ambiguous prox cap of occluded vessel, double side BASE technique can be used as a “move the cap” technique to facilitate extraplaque lesion crossing while preventing guidewire entry into the side branches & maintaining patency and access to side branches
Classification of Athletes by Age .
1.Prepubertal athletes . (<12 years of age)
2. Adolescent athletes (middle and high school; 12 - 17 years of age)
3.Young adult athletes (college and professional (18-25 years )
4.Adult athletes ( 25 -35 years of age)
5.Masters athletes (>_ 35 years of age)
#Pleasure to be part of this article team
journals.lww.com/annals-of-me...
For Pt with Liver disease (Child pugh Class B)
& AFib requiring NOACS ,which agent is contraindicated
1.Apixaban
2.Dabigatran
3.Rivaroxaban
4.Edoxaban
#CardioSky
#Coronory -Imaging
Treatment Modalities of ISR.
A.Basic Treatment.
1.DES
2.DCB
B.Adjunctive treatments.
1.Balloons based .
▪︎High Pressure NC
▪︎Scoring
▪︎Cutting
2.Waves based
▪︎IVL
▪︎Excimer Laser using ultraviolet rays
▪︎IVBT ( intravascular brachytherapy gamma & beta isotopes
3.Ablative therapies
â—ŹAngioseal is a collagen based vascular closure device
â—ŹPerclose Proglide is a suture based vascular closure device
There r 2 Fascia Layers
1.Fascia Lata
2.Fascia Iliaca
Femoral Vein & Artery are located b/w Fascia Lata & Iliaca ,while Femoral Nerve is located more laterally belowFacia Iliaca .
If we inject near Femoral artery ,it will result inadequate analgesia due to barrier of fascia
.
I’m excited to introduce our #AtheroTalk podcast! The first three episodes are live, and we’d love for you to tune in. Your feedback means the world to us—listen and share your thoughts!
#CardioSky #MedSky #Science #Podcast #atherosclerosis #ImmunoSky #EAS
open.spotify.com/show/2zYZmr7...
#LP(a)
It is new emerging risk factor for ASCVD .
HTN in Diabetics
#BPROAD trial showed that in patients with type 2 DM & HTN with elevated CV risk, intensive treatment targeting SBP ≤120 mm Hg reduced the incidence of MACE at 5 years compared with standard treatment targeting ≤140 mm Hg.
(SPRINT Trial was in Nondiabetics)
I will share
Through harmonal & metabolic pathways
#HFpEF
#Obesity is main driver for HFpEF through visceral Adipose tissue & it leads to plasma volume expansion, as well as myocardial injury and fibrosis. In turn, this results in increased LV filling coupled with a decreased ability of the LV to tolerate that filling
(Obesity =HFpEF)
#HFpEF
#AHA
Great news for obesity related Heart Failure .
Tirzepatide significantly cut risk of CV mortality and worsening heart failure events by 40% over a median follow-up of 2 years in patients with obesity and heart failure with preserved ejection (HFpEF) based on results of SUMMIT trial
#Crossword
#CardioSky
#TCTMD
Solve the Quiz